MRSA-iPLEX provided optimal throughput for MRSA genotyping, and was, on a reagent basis, more cost-effective than the real-time PCR methods. Sequence variation in the MRSA-iPLEX primer targets accounted for the majority of MRSA-iPLEX erroneous results, highlighting the importance of primer target selection. With real-time PCR as the reference standard, MRSA-iPLEX correctly assigned 2298 of the 2352 (97.7%) markers. A total of 2352 markers belonging to 44 SNP-binary profiles were analysed by both real-time PCR and MRSA-iPLEX. The method was evaluated with 147 MRSA isolates, and the results were compared with those of an established SYBR Green-based real-time PCR system utilizing the same SNP-binary markers. A 16-plex MassARRAY iPLEX GOLD assay (MRSA-iPLEX) was developed that targets a set of informative SNPs and binary genes for MRSA characterization. In this study, we investigated the use of iPLEX MassARRAY technology for methicillin-resistant Staphylococcus aureus (MRSA) genotyping. With headquarters in San Diego, California, Agena markets our products in over 30 countries worldwide through direct sales offices in Germany, China and Australia, and through an extensive network of distributors.Īgena Bioscience is a subsidiary of Mesa Labs, Inc.The Sequenom MassARRAY iPLEX single-nucleotide polymorphism (SNP) typing platform uses matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) coupled with single-base extension PCR for high-throughput multiplex SNP detection. About Agena Bioscience:Īgena Bioscience ® offers the MassARRAY ® System, an open platform that enables labs to provide a highly multiplexed result in a simple workflow. nRichDX helps solve one of precision medicine's greatest problems – – inaccurate or incomplete diagnostic results for liquid biopsy-based applications due to insufficient analyte. Unlike other methods, Revolution sample prep doesn't require yield-lowering sample pooling, bead recycling, or sample transfer steps. It is the first and only high-yield, high-recovery, IVD-labeled sample prep platform that can process from 1 mL - 20 mL of plasma or urine sample volumes and 1 mL – 40 mL of blood in a single extraction using the company's unique nRicher Cartridge™. The patented Revolution Sample Prep System™ was engineered specifically for liquid biopsy applications. NRichDX® is an emerging leader in sample prep solutions for the isolation of cfDNA, ctDNA, RNA and other rare analytes. "The combination of the Agena MassARRAY and Revolution Sample Prep System platforms represents a meaningful advancement for liquid biopsy development," he said.
"More sensitive detection of rare cancer markers translates to the earlier detection and treatment of cancer…the shared goal of liquid biopsy test developers and oncologists," said William Curtis, CEO for nRichDX. "Liquid biopsy test developers are looking forward to the creation of highly sensitive assays that can use body fluids as inputs, especially in the area of early detection of cancer which requires extraction retrieval and detection of the rarest of alterations" he said.
"Agena is pleased to collaborate with nRichDX to provide clinical investigators with research solutions that can deliver greater assay sensitivity and improved detection of rare analytes on the MassARRAY platform." said Darryl Irwin, Vice President of Scientific Affairs at Agena Bioscience. Together, these systems are a welcomed advancement towards the detection of rare cancer genetic targets in liquid biopsy samples, which have applications in the area of cancer detection, therapy selection, treatment monitoring and minimal residual disease. The Revolution Sample Prep System routinely extracts higher yields of even the rarest of variant transcripts from bodily fluids as compared to other methods, which in turn increases the detection sensitivity of the MassARRAY platform. The early detection of rare oncology analytes is the primary goal of liquid biopsy research and development however, existing methods of analyte extraction are not often able to extract sufficient rare analytes, like circulating cell-free tumor DNA (ctDNA), to enable the development of highly sensitive liquid biopsy-based assays. SAN DIEGO and IRVINE, Calif., Ap/PRNewswire/ - Agena Bioscience and nRichDX have advanced their existing technical collaboration to a commercial partnership that co-promotes their products to researchers developing liquid biopsy applications on the Agena MassARRAY platform.
NRichDX Revolution Sample Prep System™ for cfDNA Extraction and Agena's MassARRAY ® Platform for Detection of Rare Liquid Biopsy Analytes
0 kommentar(er)
